We have chosen from Table 1 to study the possible involvement of clusterin (CLU) in L1-mediated CRC progression, since CLU was found to be elevated in the serum of patients in a variety of cancers including CRC [16–19] and also in tumors of the Min mouse model of activated Wnt signaling [20]. Here, CLU is linked to colorectal carcinoma.